FundRx is a venture capital firm based in New York, NY. Our charter is to fund, support, and build high impact healthcare and life science startups pursuing novel research and new models of care. We work closely with physicians, scientists, and industry partners to ensure quality companies receive the resources they need to move their innovations from the lab to the clinic.
Zeshan MuhammediChief Executive Officer
Zeshan is a founder of FundRx and serves as its Chief Executive Officer.
Zeshan is a serial entrepreneur, having previously held senior management positions at four startup ventures. Most recently, Zeshan led business development efforts for AVARX (now deals.bio), a healthcare M&A/licensing database and technology platform built by Torreya Partners, a leading boutique healthcare investment bank.
Prior to AVARX, Zeshan was Managing Partner at Tensile Co, a global venture development firm. Zeshan holds a BS degree from Emory University.
Justin MartinChief Technology Officer
Justin is a founder of FundRx and serves as its Chief Technology Officer.
Justin is a Software Craftsman and serial entrepreneur, having held senior technical and advisory roles at over ten startup ventures. Prior to FundRx, Justin co-founded Airworthy, an aviation technology company, building both web and mobile solutions benefiting pilots and engineers. Previously, he served as an early and lead engineer at notable startups such as Handy and Groupon.
Justin left the electrical engineering program at UIUC - where he was a Presidential Honors Scholar - to pursue a formal software engineering apprenticeship at 8th Light.
Gurdane BhutaniManaging Partner
Gurdane is a founder of FundRx and serves as Managing Partner.
Prior to FundRx, Gurdane worked in the New York office of Bain & Company as a consultant to clients across the financial services, private equity, and technology sectors. Previously, Gurdane worked in the Public Finance Investment Banking group at Morgan Stanley. He was also on the team that launched StartUp Health, a leading accelerator for Digital Health startups.
Gurdane holds degrees in Computer Science (BA), Public Policy (BA), and Economics (Min.) from Duke University, where he was an Angier B Duke scholar. He also attended Oxford University as a recipient of the Lord Rothermere Scholarship.
Eric Golding, MDPartner
Dr. Eric Golding is a partner at FundRx and serves on the firm's Investment Committee.
Dr. Golding is a physician by training with extensive investment experience in both private and public markets. Most recently, Dr. Golding was a Vice President at Consonance Capital, a healthcare-only long/short hedge fund with ~$1B AUM specializing in biopharmaceuticals, medical devices, diagnostics, and healthcare IT.
Prior to joining Consonance, he was a Principal at Fidelity Biosciences (now F-Prime Capital Partners), a global venture capital firm with ~$1B AUM specializing in biopharmaceuticals, medical devices, diagnostics, and healthcare services/IT. While at Fidelity, he was a Board Observer for Iora Health, an IT-enabled healthcare services company focused on building and operating de novo primary care practices. He was also a Board Observer for Symbiomix Therapeutics, a company focused on developing therapeutics in the area of women’s health.
Dr. Golding completed his training in Internal Medicine at Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School. He gained insight into the area of pharmaceutical regulation through an internship at the Food and Drug Administration in the Office of Regulatory Policy. He holds an MD from the Yale School of Medicine and an MBA from the Yale School of Management. He received a BA from the University of Pennsylvania, where he graduated summa cum laude.
Aran Ron, MDPartner
Dr. Aran Ron is a partner at FundRx and serves on the firm's Investment Committee.
Dr. Ron is a physician trained in internal medicine at New York Hospital and received his MBA/MPH at Columbia University. He is one of the original founders, and until recently, the Chief Medical Officer of Oscar Health Plan and of Pager. He is the former President and Chief Operating Officer of Group Health Inc. (a $3 billion health plan), was Medical Director at Oxford Health Plan and at New York Downtown Hospital.
Dr. Ron previously served as CEO of Partners Health Plan (a special needs MLTC plan) and an Operating Partner at Bessemer Venture Partners. He has published articles in medical journals, serves on local and national committees such as URAC and on not-for profit boards such as St. Christopher Inc and the Metropolitan Council on Poverty. He also lectures at Cornell Medical College (where he has received a best teacher of the year award) and Columbia Business School.
Dr. Ron is also an investor, board member and consultant to various early stage companies including Oscar (recently raised $400m at a $2.7b valuation), Pager (raised a B round at $45m valuation), Data Driven Delivery System (recently sold for $400m) Dunn Meadow Pharmacy (raising a B round), ControlRad (raised a series B), Nalari Home Monitoring Company, PriceFalls, Acuity Driven Systems (raised $14m for Series A) , as well as an advisor and LP to Israel BioMed Fund, G20 Tech Fund and LifeForce Capital Fund.
Autri is a Director at FundRx. Previously, Autri was an associate in Huron’s Life Sciences Strategy practice (legacy Frankel Group) where he worked on a wide range of commercial projects for pharmaceutical and biotechnology companies.
He holds degrees in Biology (BS), History (BA), and Chemistry (Min.) from Duke University.
Chris Duff, MDDirector
Dr. Chris Duff is a Director at FundRx.
Dr. Duff is a physician by training with marketing expertise across a wide array of industries. Previously, he led campaign strategy for LaunchBoom, a marketing agency specializing in crowdfunding campaigns on Kickstarter and Indiegogo. He also co-founded Physiologic Technology, which utilized existing smart scale technology to help physicians administer individualized diuretic-dosing instructions at low cost.
Chris holds both his M.D. and undergraduate degree from the University of Illinois, where he graduated with Highest Honors.
Rahim is a Director at FundRx.
Prior to FundRx, Rahim worked at Huron Consulting Group (formerly Frankel Group) in the Life Sciences division, working exclusively with biotech, pharma, and health tech clients. Previously, Rahim worked in the Business Development and Corporate Strategy team at Alexion Pharmaceuticals, and spent a summer in Nairobi, Kenya developing a science curriculum for a network of schools in the Kibera slum.
Rahim holds degrees in Molecular Biology (BS) and Computer Science (BS) from Yale University.
Darryl FinktonSpecial Partner
Darryl is a Special Partner at FundRx.
Most recently, Darryl led the Patient Access & Reimbursement efforts within the Market Analysis & Strategy group at Genentech. In this role, Darryl guided the Commercial Executive team through a rapidly changing and polarizing pricing and reimbursement environment.
Prior to this role, Darryl drove the clinical, financial, and data strategy for providers transitioning from fee-for-service to value-based care with Evolent Health. He also guided healthcare executives through major industry changes such as the Affordable Care Act as a consultant for McKinsey & Company.
Outside of the US, Darryl has worked relentlessly to improve access to care for those in low-income communities. As Co-Founder of Clean Acwa, he has worked with local governments and NGOs to deliver potable water supplies and sanitation facilities to over 100 villages.
Darryl has an MPH and MSc in Obstetrics & Gynecology from the University of Oxford, where he studied as Rhodes Scholar and published multiple manuscripts on Maternal and Child Health worldwide. He received his undergraduate degree in Neurobiology from Harvard University.
Zachary FrankelSpecial Partner
Zach is a special partner at FundRx.
Zach is a trained physicist and investor with experience at 1/0 Capital, Founders Fund, and Goldman Sachs. Previously, Zach initiated data efforts at the Global Viral Forecasting Initiative, which develops technologies to understand, monitor, and analyze biological threats.
Zach holds an undergraduate degree from Harvard, where he was valedictorian, and then pursued a D.Phil from Oxford, where he was a Rhodes Scholar.
Jainal BhuiyanSpecial Partner
Jainal is a founder of FundRx and serves as Special Partner.
Jainal is an early-stage global healthcare investment banker with over a decade of experience. He serves as Partner and Managing Director at HRA Capital, a healthcare investment bank based in New York.
Prior to Highline, Jainal served as Senior Vice President at Rodman & Renshaw, where he led the healthcare equity capital markets effort for public and privately held companies. During his time at Rodman, he transacted on over $1 billion of domestic and cross-border deal financings and M&A. Early in his career, he served as a Senior Analyst at Provident Healthcare Partners, LLC, a Boston-based boutique M&A firm focused on healthcare services.
Jainal founded and manages ILM Pharma, a healthcare consulting and investment company based in Fort Lauderdale, focused primarily on generic and specialty pharmaceutical drug development. He is a founder and Vice President of the not-for-profit Diwan Foundation, based in Ithaca, NY.
He holds a Bachelor of Science degree from Cornell University's Charles H. Dyson School of Applied Economics and Management. He holds FINRA Series 7, Series 63 and Series 79 licenses.
Sue Huey ChuahSpecial Partner
Sue is a Special Partner at FundRx, leading the firm's efforts in Asia-Pacific.
Previously, Sue has held various corporate, venture capital, and transaction advisory positions at Medtronic, Ernst & Young, and DFJ VinaCapital.
Sue holds a BSc. Pharmacy from the National University of Singapore, MSc. in Wealth Management from Singapore Management University and an Executive MBA from Columbia Business School, HKU Business School and London Business School.
John Adler, MDAdvisor
John Adler, MDAdvisor
Dr. John R. Adler is the Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology (courtesy) at Stanford University. He is widely credited with creating the field of image-guided radiosurgery and was the inventor of the Cyberknife surgical instrument. His research has been instrumental in the treatment of tumors (& other lesions) involving the head & neck, spine, chest, abdomen and pelvis.
Dr. Adler is also an author of more than 180 peer reviewed publications and book chapters, named inventor on 12 United States patents, and has served as an editor for 7 traditional peer reviewed medical journals. In 2009, Dr. Adler started the online peer reviewed medical journal and social network Cureus.com and currently serves as it’s CEO.
Joaquim Trias, PhDAdvisor
Joaquim Trias, PhDAdvisor
Dr. Joaquim Trias is the co-founder of numerous successful biotech companies, including Microcide Pharma (NASDAQ 1996), Veriscor/Vicuron (acquired by Pfizer 2005), Peninsula (acquired by J&J 2005), MC Healthtech (founded 2012), APG Therapeutics (founded 2013), Tetraphase (NASDAQ 2013), and Anthera (NASDAQ 2013).
Tim van Biesen, PhDAdvisor
Tim van Biesen, PhDAdvisor
Dr. Tim van Biesen is a Director of Bain & Company and serves as head of its Healthcare practice in the Americas. Prior to Bain, he spent 10 years as a research scientist and completed his post-doctoral work with Robert J Lefkowitz, a Nobel Laureate in Chemistry. He has also published 30 papers in peer-reviewed journals including Nature, PNAS, and the Journal of Biological Chemistry.
Pascal Housset, PhDAdvisor
Pascal Housset, PhDAdvisor
Dr. Pascal Housset is the former President of Bayer Cropscience, and serves on the Board of the Innovative Vector Control Consortium, an initiative of the Bill & Melinda Gates Foundation that aims to curtail the spread of tropical diseases such as Malaria and Dengue. He holds a PhD in molecular biology from the French Centre National de la Recherche Scientifique (CNRS).
Sign up for our briefings to stay up to date with the latest in healthcare and life science venture capital.
We also offer career and consulting opportunities at our portfolio companies and external partners.
Great! We will keep you up to date with the latest.Tell us a little more and we will reach out to you personally.
We will get back to you soon.